RT Journal Article
SR Electronic
T1 Differentiation of NSCLC patients and healthy controls by a urinary microRNA panel
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3831
DO 10.1183/13993003.congress-2020.3831
VO 56
IS suppl 64
A1 Wilke - Raamsteeboers, Aniek J.M.
A1 Groothuis-Oudshoorn, C.G.M.
A1 De Moor, A.G.J.
A1 Van Der Palen, J.A.M.
A1 De Rooij, J.
A1 Citgez, E.
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/3831.abstract
AB Background: Previous studies showed that microRNAs (miR) in tissue biopsies and blood samples are potential biomarkers for diverse types of cancer. MiRs are actively secreted to end up in the blood and pass the kidneys to be excreted through urine. Aims of this study were to investigate whether miRs in urine can be used to diagnose non-small cell lung cancer (NSCLC) and to compare diagnostic miR panels of blood and urine.Methods: We used next generation sequencing (NGS) and differential expression analyses to identify diagnostic miRs in cell-free urine and plasma of 15 stage III and IV NSCLC patients and 13 healthy individuals. An independent urine dataset derived from a previous study with 13 NSCLC patients and 15 healthy controls was used to confirm reliability.Results: Urine of NSCLC patients contained a significant increased expression of 5 miRs and this panel identified lung cancer with a sensitivity of 76%, a specificity of 92% and an AUC of 85%. In the independent urine dataset these results persisted with a sensitivity and specificity of 63% and 100% and an AUC of 73%. No differentiation could be made between plasma samples using the same miR panel, in fact a completely different miR panel was identified by differential expression analyses with only limited differentiation power.Conclusion: A 5-miR panel in urine of patients showed good diagnostic accuracy in the differentiation between NSCLC patients and healthy controls. The diagnostic potential was confirmed in an independent dataset. Remarkably there was no differentiation power of this panel in plasma samples, nor could we identify a different diagnostic miR panel.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3831.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).